Repro Net Income vs Begin Period Cash Flow Analysis
KRMD Stock | USD 3.93 0.16 3.91% |
Repro Med financial indicator trend analysis is much more than just breaking down Repro Med Systems prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repro Med Systems is a good investment. Please check the relationship between Repro Med Net Income and its Begin Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Net Income vs Begin Period Cash Flow
Net Income vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repro Med Systems Net Income account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.
The correlation between Repro Med's Net Income and Begin Period Cash Flow is -0.8. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Repro Med Systems, assuming nothing else is changed. The correlation between historical values of Repro Med's Net Income and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Repro Med Systems are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Net Income i.e., Repro Med's Net Income and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.8 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Repro Med Systems financial statement analysis. It represents the amount of money remaining after all of Repro Med Systems operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Repro Med's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repro Med Systems current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Repro Med's Enterprise Value is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 13.8M | 15.4M | 16.7M | 17.5M | Total Revenue | 23.5M | 27.9M | 28.5M | 29.9M |
Repro Med fundamental ratios Correlations
Click cells to compare fundamentals
Repro Med Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Repro Med fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.9M | 39.9M | 41.3M | 42.3M | 28.5M | 29.9M | |
Total Current Liabilities | 2.4M | 3.7M | 4.8M | 7.0M | 4.5M | 4.7M | |
Net Debt | (5.5M) | (27.1M) | (24.7M) | (12.5M) | (7.0M) | (6.7M) | |
Retained Earnings | 4.9M | 3.7M | (910.1K) | (9.6M) | (23.3M) | (22.1M) | |
Cash | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Non Current Assets Total | 2.0M | 2.4M | 4.0M | 12.5M | 8.2M | 8.6M | |
Net Receivables | 3.2M | 2.6M | 4.3M | 4.5M | 4.1M | 4.3M | |
Common Stock Total Equity | 422.4K | 466.8K | 480.4K | 488.6K | 561.9K | 373.2K | |
Liabilities And Stockholders Equity | 13.9M | 39.9M | 41.3M | 42.3M | 28.5M | 29.9M | |
Non Current Liabilities Total | 239.5K | 95.6K | 1.9M | 4.0M | 3.7M | 3.8M | |
Inventory | 2.4M | 6.8M | 6.1M | 6.4M | 3.5M | 3.7M | |
Total Liab | 2.6M | 3.8M | 4.8M | 11.0M | 8.1M | 8.5M | |
Property Plant And Equipment Gross | 985.6K | 1.2M | 1.2M | 7.7M | 10.1M | 10.6M | |
Total Current Assets | 11.9M | 37.5M | 37.3M | 29.8M | 20.3M | 21.3M | |
Intangible Assets | 807.1K | 843.6K | 808.8K | 787.2K | 754.4K | 792.1K | |
Other Current Liab | 1.7M | 2.8M | 5.6M | 3.7M | 2.7M | 2.8M | |
Total Stockholder Equity | 11.2M | 36.2M | 36.5M | 31.3M | 20.4M | 21.4M | |
Property Plant And Equipment Net | 985.6K | 1.4M | 1.2M | 7.7M | 7.4M | 7.7M | |
Accounts Payable | 572.7K | 624.9K | 1.2M | 2.4M | 975.2K | 502.6K | |
Cash And Short Term Investments | 5.9M | 27.3M | 25.3M | 17.4M | 11.5M | 12.1M | |
Common Stock Shares Outstanding | 39.1M | 41.9M | 44.4M | 45.0M | 45.6M | 37.4M | |
Other Current Assets | 387.4K | 807.8K | 3.1M | 2.9M | 1.2M | 1.3M | |
Other Stockholder Equity | 5.9M | 32.0M | 36.9M | 40.4M | 43.2M | 45.3M | |
Common Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 395.6K | |
Net Tangible Assets | 10.4M | 35.3M | 35.7M | 30.5M | 35.1M | 19.3M | |
Other Assets | 207.8K | 381.9K | 2.0M | 4.1M | 4.7M | 4.9M | |
Capital Surpluse | 6.3M | 35.9M | 40.8M | 44.3M | 50.9M | 53.4M | |
Property Plant Equipment | 985.6K | 1.4M | 1.2M | 3.9M | 4.5M | 4.7M | |
Net Invested Capital | 11.2M | 36.2M | 37.0M | 31.8M | 20.7M | 26.7M | |
Capital Stock | 422.4K | 466.8K | 480.4K | 488.6K | 490.9K | 505.7K | |
Net Working Capital | 9.5M | 33.9M | 32.5M | 22.8M | 15.8M | 22.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.26) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.